Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
imiquimod · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| imiquimod | DRUG | - |
Inclusion Criteria: * At least 18 years of age. * Have a total of 4 to 8 clinically typical, discrete, non-hyperkeratotic, non-hypertrophic AK lesions located within a contiguous 25 cm2 treatment area (balding scalp or face, but not both). * Free of any significant findings (e.g. tattoos) in the po...
Imiquimod is a small molecule being studied for the treatment of actinic keratoses, a skin condition caused by sun damage. It is in Phase 3 clinical development and is being developed by 3M Company (NYSE: MMM).
Imiquimod is a small molecule immunomodulator. It works by stimulating the immune system to fight abnormal skin cells. The specific molecular target has not been disclosed in the available information.
Imiquimod is being developed by 3M Company, which trades on the New York Stock Exchange under the ticker symbol MMM. The company is conducting clinical trials to evaluate the drug for actinic keratoses.
Imiquimod is in Phase 3 clinical development for actinic keratoses. It is an investigational drug and has not been approved by regulatory authorities. One Phase 3 trial has been completed.
Imiquimod has one completed Phase 3 trial, NCT00175643, which evaluated the safety and efficacy of the drug applied in a dose-cycle for actinic keratoses. The trial enrolled 20 participants in Canada and was not randomized or blinded.
Imiquimod is the generic name for the drug also known as Aldara. The information provided does not specify alternative names, so it is not confirmed whether imiquimod is the same as Aldara.